Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).
The analysis of the liquidity ratios reveals several notable trends over the observed periods. The current ratio, which measures the company's ability to cover short-term liabilities with short-term assets, showed an initial peak in late 2021 with a ratio exceeding 3. However, it experienced a marked decline towards the end of 2021 and early 2022, stabilizing within a narrower range around 1.5 to 1.7 in subsequent periods. Towards the latest quarters, the current ratio showed a mild upward trend, reaching close to 1.9 before a slight dip in the most recent quarter.
The quick ratio, reflecting the firm's ability to meet immediate liabilities without relying on inventory, closely mirrors the current ratio's pattern but generally remained at a lower level, often below 1.5. It declined sharply by the end of 2021, dipping close to 1 or slightly below, indicating tighter liquidity conditions during that period. Thereafter, it gradually improved, reaching approximately 1.3 in mid-2025, before slightly retreating again.
The cash ratio, which provides the most conservative measure of liquidity by comparing cash and cash equivalents to current liabilities, consistently remained lower than both the current and quick ratios throughout the period. It started high in early 2021 but quickly decreased substantially by the end of that year. The ratio exhibited some volatility thereafter, with intermittent rises and falls but generally stayed below 0.6, indicating limited cash reserves relative to short-term obligations. The latest quarter showed another reduction, suggesting a somewhat tighter cash position compared to previous periods.
- Current Ratio
- Initially high with a peak over 3, followed by a sharp decline at end-2021, then stabilization around 1.5 to 1.7, and a moderate increase near 1.9 in mid-2025 before a recent minor decrease.
- Quick Ratio
- Declined strongly at end-2021 to near or below 1, gradual recovery reaching about 1.3 in mid-2025, followed by a slight downturn in the latest quarter.
- Cash Ratio
- Started relatively strong in early 2021 but dropped sharply by end-2021, fluctuated below 0.6 afterward, with a tendency toward limited cash liquidity and a recent decrease indicating tighter immediate cash availability.
Overall, these liquidity metrics indicate a phase of strong liquidity early in the period, followed by a contraction and stabilization at more moderate levels, with some improvement in short-term asset coverage of liabilities over the most recent years. However, the conservative cash ratio suggests the company's immediate cash buffer remains limited relative to its current obligations, highlighting a potential area for attention in cash management strategies.
Current Ratio
| Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).
1 Q3 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several key trends regarding liquidity and working capital management.
- Current Assets
- Current assets exhibit a fluctuating pattern over the examined periods. Initial growth is observed from April 2021 to October 2021, peaking around 24,724 million USD. This is followed by a decrease and subsequent recovery, with notable highs in December 2022 (25,229 million USD) and mid-2024 (around 25,476 million USD). The latest periods show some volatility but generally maintain levels above 22,000 million USD. This suggests variability in liquid resources and short-term assets held by the company over time.
- Current Liabilities
- Current liabilities also display considerable fluctuation. Beginning at 6,995 million USD in April 2021, liabilities rose steadily with sharp increases observed in the last quarters of both 2021 and 2022, reaching peaks of 17,010 million USD and approximately 14,888 million USD in June 2025. The data indicates periods of increased short-term obligations, suggesting changes in company obligations or possibly financing and operational activities impacting liabilities.
- Current Ratio
- The current ratio shows a significant decline from a strong liquidity position of 2.53 in April 2021 to 1.5 by December 2021. This ratio improves gradually through 2022 and 2023, fluctuating between 1.27 and 1.75, indicating efforts to restore liquidity but remaining below initial high levels. By mid-2025, the ratio appears less stable, with values dropping back to around 1.5 after briefly reaching 1.93. Overall, liquidity has been under pressure compared to early 2021 levels, reflecting tighter short-term financial flexibility.
In summary, the company’s liquid assets and short-term liabilities have both increased but with notable volatility. The decreases in the current ratio during some periods highlight tighter short-term financial conditions, while subsequent recoveries suggest dynamic management of working capital. The overall trend points to periods of stress followed by partial stabilization, emphasizing the need for ongoing monitoring of liquidity to sustain operational effectiveness.
Quick Ratio
| Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||||||
| Accounts receivable, less allowances | |||||||||||||||||||||||||
| Contract assets, net | |||||||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).
1 Q3 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Total Quick Assets
- The total quick assets displayed notable fluctuations over the analyzed periods. Initially, the value rose from $11,920 million to a peak of $18,392 million by October 2021, followed by a decline to around $11,705 million in April 2022. A significant recovery occurred by December 2022, reaching $17,951 million again. Subsequently, there were oscillations with values ranging mostly between $12,600 million and $18,200 million, with the highest recent value recorded in June 2024 at $18,253 million. However, in the latest quarter ending September 2025, quick assets decreased to approximately $14,077 million, indicating some volatility and potential variability in liquid asset holdings.
- Current Liabilities
- Current liabilities followed an overall increasing trend with occasional declines. Starting at $6,995 million in April 2021, liabilities sharply increased to $13,436 million by December 2021, effectively nearly doubling within the year. Though there was some reduction to around $10,997 million by mid-2022, liabilities surged again to approximately $17,010 million in December 2022. The subsequent quarters exhibited a gradual decline peaking near $14,888 million in June 2025, but the values remained generally higher than in the initial periods, suggesting increased short-term obligations or operational scale expansions over time.
- Quick Ratio
- The quick ratio exhibited significant variability, reflecting changes in liquidity relative to current liabilities. Starting at a healthy 1.7 times in April 2021, it improved further to 2.37 in October 2021, demonstrating strong short-term liquidity. However, by December 2021, this ratio dropped sharply to 1.0 and dipped below 1.0 in April and July 2022, indicating periods where quick assets slightly lagged current liabilities. From the latter part of 2022 through mid-2024, the quick ratio modestly improved and stabilized mostly above 1.0, ranging between 1.13 and 1.29, suggesting better liquidity management during these periods. Yet, the most recent quarter ending in September 2025 shows a decline to 0.95, hinting at a potential tightening of liquidity or increased current liabilities relative to quick assets.
- Overall Insights
- The financial data reveals cyclical patterns in liquidity and obligations, with significant swings in both quick assets and current liabilities. Peaks in quick assets often correspond with increases in current liabilities, resulting in fluctuating quick ratios that reflect varying liquidity strengths. The periods of rapid increase in current liabilities may indicate expanded operational activity or short-term financing needs, while recovery in quick assets suggests efforts to maintain liquid resources. However, the variability in the quick ratio, especially dips below 1.0, highlights periods where the company’s liquidity position was relatively weaker. The recent downward trend in quick assets combined with a decline in the quick ratio could warrant further attention to ensure adequate short-term financial stability moving forward.
Cash Ratio
| Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03).
1 Q3 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends and fluctuations in the company's liquidity position and short-term obligations over the observed periods.
- Total Cash Assets
- The total cash assets exhibit significant variability across the quarters. Starting at a moderate level of 5,583 million USD in early April 2021, cash assets peaked at 12,027 million USD by October 2021, capturing a substantial increase. However, this was followed by a notable decline towards the end of the same year, falling to 4,477 million USD by December 2021. The subsequent quarters saw cash assets generally fluctuate, with a low point around 1,888 million USD in mid-2022, a recovery to 8,080 million USD by the end of 2023, and another decline reaching down to 3,546 million USD by the third quarter of 2025. This pattern suggests intermittent cash inflows and outflows, possibly linked to operational cycles, capital expenditures, or financing activities.
- Current Liabilities
- Current liabilities have steadily increased over the observed timeframe, though with some oscillations. Starting from 6,995 million USD in April 2021, current liabilities rose sharply towards the end of 2021, reaching a peak of 17,010 million USD in December 2022. Thereafter, current liabilities generally trended downward but remained elevated relative to the starting point, with values fluctuating between roughly 12,700 million and 15,000 million USD through mid-2025. The increasing trend in liabilities indicates potentially greater short-term obligations, which could affect liquidity pressure if not matched by corresponding assets or revenue.
- Cash Ratio
- The cash ratio, which measures the company's ability to cover current liabilities with cash assets, shows a declining pattern overall. It started at 0.8 in April 2021, subsequently rising to a peak of 1.55 in October 2021, indicating strong liquidity at that moment. However, this was followed by a sharp drop to 0.33 in December 2021 and even lower levels in mid-2022, dipping as low as 0.17. Some recovery was observed in 2023, with ratios around 0.5 to 0.6, but by the third quarter of 2025, the ratio had fallen again to 0.24. This downward trend in the cash ratio suggests that despite intermittent recoveries, the company’s immediate liquidity relative to its short-term obligations has generally diminished, potentially raising concerns over its capacity to meet current liabilities promptly with cash on hand.
In summary, the company has experienced substantial volatility in cash assets, a rising trend in current liabilities, and a general decline in its cash ratio over the examined quarters. The fluctuation in cash assets paired with increasing liabilities and a weakening cash ratio highlights potential liquidity management challenges, requiring close monitoring to ensure adequate short-term financial stability.